Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis

References

• Ljosaa TM, Rustoen T, Mörk C, et al. Skin pain and discomfort in psoriasis: an exploratory study of symptom prevalence and characteristics. Acta Derm Venerol. 2010;90(1):39–45.
   PubMed Web of Science ®Google Scholar
• Hrehorów E, Salomon J, Matusiak L, et al. Patients with psoriasis feel stigmatized. Acta Derm Venereol. 2012;92(1):67–72.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Schupp C, Wu J, et al. Quality of life and work productivity impairment among psoriasis patients: findings from the national psoriasis foundation survey data 2003-2011. PLOS One. 2012;7(12):e52935.
   PubMed Web of Science ®Google Scholar
• Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013;3:Cd005028.
   PubMed Web of Science ®Google Scholar
• Körber A, Wilsmann-Theis D, Augustin M, et al. Topische therapie bei psoriasis vulgaris – ein behandlungspfad. JDDG: Journal Der Deutschen Dermatologischen Gesellschaft. 2019;17(S4):3–14.
   Google Scholar
• Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):119–126.
   PubMed Web of Science ®Google Scholar
• Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris–a randomized phase II study. J Dermatolog Treat. 2016;27(2):120–127.
   PubMed Web of Science ®Google Scholar
• Yélamos O, Alejo B, Ertekin SS, et al. Non-invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator-initiated, phase IV, unicentric, open, randomized clinical trial. J Eur Acad Dermatol Venereol. 2021;35(1):143–149.
   PubMed Web of Science ®Google Scholar
• Basse LH, Olesen M, Lacour JP, et al. Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle. J Invest Dermatol. 2014;134.S33:abst 192.
   Web of Science ®Google Scholar
• Pinter A, Green LJ, Selmer J, et al. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. Acad Dermatol Venereol. 2022;36(2):228–236.
   PubMed Web of Science ®Google Scholar
• Stein Gold L, Green L, Dhawan S, et al. A phase 3, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol. 2021;20(4):420–425.
   PubMed Web of Science ®Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200–211.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947.
   PubMed Web of Science ®Google Scholar
• Bewley AP, Shear NH, Calzavara-Pinton PG, et al. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison. J Eur Acad Dermatol Venereol. 2019;33(6):1107–1115.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. J Med Econ. 2020;23(6):641–649.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935–945.
   PubMed Web of Science ®Google Scholar
• clinicaltrials.gov. NCT03308799 2019 [cited 2021 September]. Available from: https://clinicaltrials.gov/ct2/show/NCT03308799.
   Google Scholar
• clinicaltrials.gov. NCT03802344 2020 [cited 2021 September]. Available from: https://clinicaltrials.gov/ct2/show/NCT03802344.
   Google Scholar
• Leonardi C, Bagel J, Yamauchi P, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris–a randomized phase III study (PSO-FAST. J Drugs Dermatol. 2015;14:1468–1477.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (cal) Plus betamethasone dipropionate 0.064% (BD) is more efficacious than cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase 2 study. J Clin Aesthet Dermatol. 2016;9:34–41.
   PubMedGoogle Scholar
• Lebwohl M, Kircik L, Lacour JP, et al. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). J Am Acad Dermatol. 2021;84(5):1269–1277.
   PubMed Web of Science ®Google Scholar
• LEO Pharma. Enstilar Cutaneous Foam, Summary of Product Characteristics 2021. [cited 2021 April 14]. Available from: https://www.medicines.org.uk/emc/product/2139/smpc.
   Google Scholar
• Puig L, Carretero G. Update on topical treatments for psoriasis: the role of calcipotriol plus betamethasone dipropionate aerosol foam. Actas Dermosifiliogr. 2019;110(2):115–123.
   PubMed Web of Science ®Google Scholar
• Rudnicka L, Olszewska M, Goldust M, et al. Efficacy and safety of different formulations of calcipotriol/betamethasone dipropionate in psoriasis: gel, foam, and ointment. J Clin Med. 2021;10:5589.
   PubMed Web of Science ®Google Scholar
• Lind M, Nielsen KT, Schefe LH, et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for topical treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther. 2016;6(3):413–425.
   PubMed Web of Science ®Google Scholar
• Wu AG, Conway J, Barazani L, et al. Is clear always clear? Comparison of psoriasis area and severity index (PASI) and the physician's global assessment (PGA) in psoriasis clearance. Dermatol Ther. 2020;10(5):1155–1163.
   Web of Science ®Google Scholar
• Hampton P, Borg E, Hansen JB, et al. Efficacy of brodalumab and guselkumab in patients with moderate-to-severe plaque psoriasis who are inadequate responders to ustekinumab: a matching adjusted indirect comparison. PTT. 2021;ume 11:123–131.
   Web of Science ®Google Scholar
• Papp KA, Yang M, Sundaram M, et al. Comparison of adalimumab and etanercept for the treatment of moderate to severe psoriasis: an indirect comparison using individual patient data from randomized trials. Value Health. 2018;21(1):1–8.
   PubMed Web of Science ®Google Scholar
• Warren RB, Brnabic A, Saure D, et al. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. Br J Dermatol. 2018;178(5):1064–1071.
   PubMed Web of Science ®Google Scholar